Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Howard Jonas Biography and Net Worth

CEO of Rafael

Howard S. Jonas serves as Chairman of the Board of Directors of the Company and Chief Executive Officer. Mr. Jonas has been a director of Rafael Pharmaceuticals since April 2013 and was appointed Chairman of the Board in April 2016. Mr. Jonas founded IDT in August 1990, and has served as Chairman of its Board of Directors since its inception. Mr. Jonas has served as Chief Executive Officer of IDT from October 2009 through December 2013. Mr. Jonas has served as Chairman of the Board of Directors of Genie Energy Ltd. since January, 2011, when it was spun off from IDT, and as Chief Executive Officer of Genie since January 2014. He has served as Co-Vice Chairman of Genie’s subsidiary, Genie Energy International Corporation, since September 2009. He has been a director of IDT Energy since June 2007 and a director of American Shale Oil Corporation LLC since January 2008. Mr. Jonas served as the Chairman of the Board of Zedge, Inc., a former subsidiary of IDT that was spun off to stockholders in June 2016, from June 2016 to November 2016, and as the Vice Chairman of Zedge since November 2016. Mr. Jonas also serves as the Chairman of the Board of IDW Media Holdings, Inc., a former subsidiary of IDT that was spun off to stockholders in September 2009. Mr. Jonas is also the founder and has been President of Jonas Media Group (f/k/a Jonas Publishing) since its inception in 1979. Mr. Jonas received a B.A. in Economics from Harvard University.

What is Howard S. Jonas' net worth?: The estimated net worth of Howard S. Jonas is at least $5.71 million as of July 6th, 2022. Mr. Jonas owns 3,338,367 shares of Rafael stock worth more than $5,708,608 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Jonas may own. Additionally, Mr. Jonas receives an annual salary of $40,000.00 as CEO at Rafael. Learn More about Howard S. Jonas' net worth.
How old is Howard S. Jonas?: Mr. Jonas is currently 68 years old. There are 5 older executives and no younger executives at Rafael. Learn More on Howard S. Jonas' age.
What is Howard S. Jonas' salary?: As the CEO of Rafael Holdings, Inc., Mr. Jonas earns $40,000.00 per year. There are 2 executives that earn more than Mr. Jonas. The highest earning executive at Rafael is Mr. William Conkling, CEO & President, who commands a salary of $751,950.00 per year. Learn More on Howard S. Jonas' salary.
How do I contact Howard S. Jonas?: The corporate mailing address for Mr. Jonas and other Rafael executives is 520 BROAD STREET, NEWARK NJ, 07102. Rafael can also be reached via phone at (212) 658-1450 and via email at [email protected]. Learn More on Howard S. Jonas' contact information.
Has Howard S. Jonas been buying or selling shares of Rafael?: Howard S. Jonas has not been actively trading shares of Rafael in the last ninety days. Most recently, on Wednesday, July 6th, Howard S. Jonas bought 3,225,806 shares of Rafael stock. The stock was acquired at an average cost of $1.86 per share, with a total value of $5,999,999.16. Following the completion of the transaction, the chairman now directly owns 3,338,367 shares of the company's stock, valued at $6,209,362.62. Learn More on Howard S. Jonas' trading history.

Howard S. Jonas Insider Trading History at Rafael

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/6/2022	Buy	3,225,806	$1.86	$5,999,999.16	3,338,367
8/24/2021	Buy	112,561	$44.92	$5,056,240.12

Howard S. Jonas Buying and Selling Activity at Rafael

Rafael Company Overview

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Today's Range

Now: $1.71

$1.67

$1.75

50 Day Range

MA: $1.74

$1.66

$1.90

2 Week Range

Now: $1.71

$1.44

$2.52

Volume

7,625 shs

Average Volume

24,474 shs

Market Capitalization

$42.03 million

P/E Ratio

17.10

Dividend Yield

N/A

Beta

1.32